Cover Image
Read Now

Clinical review report: Eliglustat (Cerdelga) (Sanofi Genzyme) : indication: Gaucher disease type 1

The objective of this report was to perform a systematic review of the beneficial and harmful effects of eliglustat 84 mg capsules for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 2D6 (CYP2D6) poor metabolizers, intermediate metabolizers, or extensive m...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, August 2017
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Adult
Canada
Enzyme Replacement Therapy / Adverse Effects
Cytochrome P-450 Cyp2d6 Inhibitors / Therapeutic Use
Treatment Outcome
Gaucher Disease / Drug Therapy
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this report was to perform a systematic review of the beneficial and harmful effects of eliglustat 84 mg capsules for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 2D6 (CYP2D6) poor metabolizers, intermediate metabolizers, or extensive metabolizers
Physical Description:1 PDF file (93 pages) illustrations

Similar Items